Literature DB >> 8760797

Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens.

M E Dudley1, D C Roopenian.   

Abstract

Most chemically induced tumors of mice express unique antigens that can be recognized by cytotoxic T lymphocytes (CTL) and thereby mediate tumor rejection. The number of different antigens expressed by a single tumor and their interplay during immunization and rejection are largely unexplored. We used CTL clones specific to individual tumor antigens to examine the number and distribution of CTL antigens expressed by cell lines derived from 3-methylcholanthrene-induced sarcomas of (C57BL/6J X SPRET/Ei)F1 mice. Each tumor cell line expressed one or more antigens that were unique, that is, not detected on cell lines from independent sarcomas. Immunoselection against an immunodominant antigen produced both major histocompatibility complex class I antigen and unique tumor antigen loss variants. Immunization of mice with antigen-negative immunoselected variants resulted in CTL that recognized additional antigens that were also expressed by the progenitor tumor. Some CTL recognized additional unique tumor antigen(s); other CTL recognized a shared antigen expressed not only by the immunizing cell line, but also by independent sarcoma cell lines and untransformed myoblastoid cell lines. CTL that recognized the shared antigen were also recovered from mice immunized in vivo with an untransformed myoblastoid cell line. These findings support a model of immunodominance among chemically induced tumor antigens in which shared antigens are masked by unique immunodominant antigens.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8760797      PMCID: PMC2192736          DOI: 10.1084/jem.184.2.441

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  26 in total

1.  Responses against single minor histocompatibility antigens. II. Analysis of cloned helper T cells.

Authors:  D C Roopenian; C G Orosz; F H Bach
Journal:  J Immunol       Date:  1984-03       Impact factor: 5.422

2.  Search for common antigenicities among twenty-five sarcomas induced by methylcholanthrene.

Authors:  M A Basombrío
Journal:  Cancer Res       Date:  1970-10       Impact factor: 12.701

3.  Multiple lineages of tumors express a common tumor antigen, P1A, but they are not cross-protected.

Authors:  L Ramarathinam; S Sarma; M Maric; M Zhao; G Yang; L Chen; Y Liu
Journal:  J Immunol       Date:  1995-12-01       Impact factor: 5.422

4.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

Authors:  P van der Bruggen; C Traversari; P Chomez; C Lurquin; E De Plaen; B Van den Eynde; A Knuth; T Boon
Journal:  Science       Date:  1991-12-13       Impact factor: 47.728

5.  Multiple tumour-specific antigens expressed on a single tumour cell.

Authors:  R D Wortzel; C Philipps; H Schreiber
Journal:  Nature       Date:  1983 Jul 14-20       Impact factor: 49.962

6.  Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. IV. Analysis of variant-specific antigens by selection of antigen-loss variants with cytolytic T cell clones.

Authors:  J L Maryanski; T Boon
Journal:  Eur J Immunol       Date:  1982-05       Impact factor: 5.532

7.  Stepwise immunologic selection of antigenic variants during tumor growth.

Authors:  J L Urban; M L Kripke; H Schreiber
Journal:  J Immunol       Date:  1986-11-01       Impact factor: 5.422

8.  Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy.

Authors:  S Y Shu; T Chou; S A Rosenberg
Journal:  J Immunol       Date:  1987-07-01       Impact factor: 5.422

9.  Cellular interactions and the role of interleukin 2 in the expression and induction of immunity against a syngeneic murine sarcoma.

Authors:  T Chou; S Shu
Journal:  J Immunol       Date:  1987-09-15       Impact factor: 5.422

10.  Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes.

Authors:  R J Barth; S N Bock; J J Mulé; S A Rosenberg
Journal:  J Immunol       Date:  1990-02-15       Impact factor: 5.422

View more
  15 in total

1.  Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes.

Authors:  Xue-Feng Bai; Jinqing Liu; Ou Li; Pan Zheng; Yang Liu
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

2.  Diversity of escape variant mutations in Simian virus 40 large tumor antigen (SV40 Tag) epitopes selected by cytotoxic T lymphocyte (CTL) clones.

Authors:  Lawrence M Mylin; Todd D Schell; Melanie Epler; Caroline Kusuma; David Assis; Chelsea Matsko; Alexandra Smith; April Allebach; Satvir S Tevethia
Journal:  Virology       Date:  2007-03-21       Impact factor: 3.616

3.  Tumor-derived autophagosome vaccine: induction of cross-protective immune responses against short-lived proteins through a p62-dependent mechanism.

Authors:  Christopher G Twitty; Shawn M Jensen; Hong-Ming Hu; Bernard A Fox
Journal:  Clin Cancer Res       Date:  2011-08-02       Impact factor: 12.531

Review 4.  Rejection antigens in chemically induced tumors.

Authors:  G Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

5.  Mutated mitogen-activated protein kinase: a tumor rejection antigen of mouse sarcoma.

Authors:  H Ikeda; N Ohta; K Furukawa; H Miyazaki; L Wang; K Kuribayashi; L J Old; H Shiku
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

Review 6.  Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other".

Authors:  W W Overwijk; N P Restifo
Journal:  Crit Rev Immunol       Date:  2000       Impact factor: 2.214

7.  Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.

Authors:  Valsamo Anagnostou; Kellie N Smith; Patrick M Forde; Noushin Niknafs; Rohit Bhattacharya; James White; Theresa Zhang; Vilmos Adleff; Jillian Phallen; Neha Wali; Carolyn Hruban; Violeta B Guthrie; Kristen Rodgers; Jarushka Naidoo; Hyunseok Kang; William Sharfman; Christos Georgiades; Franco Verde; Peter Illei; Qing Kay Li; Edward Gabrielson; Malcolm V Brock; Cynthia A Zahnow; Stephen B Baylin; Robert B Scharpf; Julie R Brahmer; Rachel Karchin; Drew M Pardoll; Victor E Velculescu
Journal:  Cancer Discov       Date:  2016-12-28       Impact factor: 39.397

Review 8.  Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer Evolution.

Authors:  Subramanian Venkatesan; Charles Swanton; Barry S Taylor; Joseph F Costello
Journal:  Cold Spring Harb Perspect Med       Date:  2017-08-01       Impact factor: 6.915

Review 9.  Specificity in cancer immunotherapy.

Authors:  Andrea Schietinger; Mary Philip; Hans Schreiber
Journal:  Semin Immunol       Date:  2008-08-05       Impact factor: 11.130

Review 10.  Mobilizing the low-avidity T cell repertoire to kill tumors.

Authors:  Rachel H McMahan; Jill E Slansky
Journal:  Semin Cancer Biol       Date:  2007-06-23       Impact factor: 15.707

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.